Newron's Evenamide Shows Breakthrough in Treating Resistant Schizophrenia
Newron Pharmaceuticals has made strides in schizophrenia treatment with its lead drug, news today, evenamide. Recent clinical data shows strong results, especially for patients resistant to other therapies. The company has also expanded its patent protection, securing exclusivity for its key asset until 2044.
Despite positive developments, the stock price has fluctuated, reflecting mixed market reactions to its progress.
On February 3, 2026, Newron released news today clinical findings on evenamide. The data revealed that over half of treated patients no longer met severe disease criteria after one year. Nearly a quarter reached full remission, offering hope for those struggling with treatment-resistant schizophrenia. The drug works by targeting specific signalling pathways, providing a new option where others fail.
Earlier, on January 7, 2026, Newron's partner began a Phase III trial in Japan. This move marks a key step toward global commercialisation, expanding the drug's potential reach. Meanwhile, the company strengthened its intellectual property with a new European patent, ensuring evenamide's exclusivity until 2044.
The stock initially climbed by 1.5% to 20.30 CHF after the February news today release. However, despite analyst valuations suggesting a 50% upside—pegging the fair value at 37.60 CHF—it has since dipped. Recent trading shows prices between 19.46 and 21.90 CHF/EUR, a 186% gain over six months but still below projections.
Looking ahead, Newron's 2025 annual report is due on March 24, 2026. Shareholders will meet for the annual general meeting on April 23, 2026, where further updates may be shared.
Evenamide's clinical success and patent extension position Newron strongly in schizophrenia treatment. The Phase III trial in Japan could open new markets, while the stock's performance remains cautious despite analyst optimism. The upcoming annual report and shareholder meeting will likely provide further clarity on the company's next steps.
